-
Cotation en bourse
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suiteTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLire la suiteEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
MaaT Pharma s'introduit sur Euronext Paris
09/11/2021
Hervé Affagard, co-Fondateur et Directeur Général de MaaT Pharma, ouvre les marchés financiers à Paris.
MaaT Pharma est spécialisé dans la recherche et le développement de biothérapies du microbiome destinées au traitement des tumeurs cancéreuses solides (notamment leucémie myéloïde aiguë) et de la maladie aigüe du greffon contre l’hôte (GvH).
La société dispose de 3 produits en phase de développement.